Core Viewpoint - Wuhan Heyuan Biotechnology Co., Ltd. is advancing its plant-based recombinant human serum albumin industrialization base project, which is expected to significantly impact domestic supply and health security by reducing reliance on imported products [3][5]. Group 1: Project Development - The construction of the first phase of the industrialization base is underway, with 490 workers on-site as of June 3 [1]. - The main structure of the project was completed in late April, and internal construction is currently ongoing, with equipment installation and debugging scheduled for July [3]. - The project is expected to be operational by the second quarter of 2026, with a total building area of approximately 70,000 square meters [3]. Group 2: Production Capacity and Strategic Importance - Once completed, the facility is projected to produce 12 million doses of recombinant human serum albumin injection annually, which could replace about 25% of the domestic import volume [3][5]. - The project is deemed strategically significant for public health and national defense, as it aims to ensure a stable supply of essential medical products [3][5]. Group 3: Innovation and Technology - Heyuan Biotechnology has developed the world's first plant-based recombinant human serum albumin using rice, marking a significant innovation in the field [5][6]. - The company has established a unique plant expression system and four core technology platforms, which are crucial for the development of new drugs [6].

近日，位于光谷生物城的禾元生物"稻米造血"产业化基地项目一期主体结构封顶，全面 转入设备安装与调试阶段，冲刺2026年建成投产。达产后，可年产1200万支重组白蛋白注射 液。 禾元生物董事长杨代常表示，项目建成后可实现公司研发的创新药——奥福民商业规模 化生产，对满足我国国民健康需求、摆脱长期进口依赖、确保供应链安全具有重要战略意 义。 创新药是生物医药产业的前沿领域、创新赛道，业界常用"九死一生"形容创新药从研发 到上市应用的坎坷历程。 在创新药领域，来自中国光谷的好消息不断。光谷生物城产业发展处相关负责人表 示："2024年下半年至今，正大天晴润欣、深圳福沃药业和上海甫康药业等一批创新药企业 正加速向光谷聚集。"光谷生物城招商部最新统计数据显示，今年一季度，一批创新药项目 落户光谷，签约金额近45亿元。 长三角、大湾区等沿海发达地区的"新朋友"落子光谷，带来优质创新资源；诞生于武汉 的创新药企业逐渐崭露头角，一系列前沿的、充满科幻感的创新成果正在武汉加速孕育。 "光谷拥有深厚的生物产业发展基础，我们将和光谷创新生态的优秀公司合作，加强创 新药研发。"在光谷生物城一季度招商引资大会上，上海甫康药业董事长沈孝 ...